These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19366858)

  • 1. Biosimilar epoetins.
    Macdougall IC
    Nephrol Dial Transplant; 2009 May; 24(5):1698-9; author reply 1699-700. PubMed ID: 19366858
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythropoietin, the FDA, and oncology.
    Steinbrook R
    N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
    [No Abstract]   [Full Text] [Related]  

  • 3. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin.
    Howman R; Kulkarni H
    Nephrol Dial Transplant; 2007 May; 22(5):1462-4. PubMed ID: 17314208
    [No Abstract]   [Full Text] [Related]  

  • 5. Rebates for anti-anemia drugs draw response from FDA, CMS.
    Sipkoff M
    Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
    [No Abstract]   [Full Text] [Related]  

  • 6. Managing anemia: what do we do now?
    Neumann ME
    Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful re-challenge with darbepoetin in a patient with rHu-EPO-induced pure red cell aplasia refractory to immunosuppressive drugs.
    Viron B; Dupuy CA; Kolta A; Casadevall N
    Nephrol Dial Transplant; 2008 Jul; 23(7):2416-8. PubMed ID: 18388118
    [No Abstract]   [Full Text] [Related]  

  • 8. Amgen's point of view on epoetins.
    Seidenberg B; Perlmutter RM
    Lancet Oncol; 2004 Apr; 5(4):206-7. PubMed ID: 15050950
    [No Abstract]   [Full Text] [Related]  

  • 9. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
    Yang MC
    Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
    [No Abstract]   [Full Text] [Related]  

  • 10. Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis.
    Asari A; Gokal R
    J Am Soc Nephrol; 2004 Aug; 15(8):2204-7. PubMed ID: 15284306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reimbursement for erythropoiesis-stimulating agents poses challenges.
    Traynor K
    Am J Health Syst Pharm; 2008 Mar; 65(5):385-6. PubMed ID: 18281727
    [No Abstract]   [Full Text] [Related]  

  • 12. Improvement in erythropoieis-stimulating agent-induced pure red-cell aplasia by introduction of darbepoetin-α when the anti-erythropoietin antibody titer declines spontaneously.
    Lee H; Yang J; Kim H; Kwon JW; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S
    J Korean Med Sci; 2010 Nov; 25(11):1676-9. PubMed ID: 21060762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
    Winkelmayer WC
    J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
    [No Abstract]   [Full Text] [Related]  

  • 14. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

  • 15. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
    Lappin TR; Maxwell AP; Johnston PG
    Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
    [No Abstract]   [Full Text] [Related]  

  • 16. Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.
    Nakagawa T
    Ther Apher Dial; 2008 Dec; 12(6):531-2. PubMed ID: 19140854
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythropoietin: high profile, high scrutiny.
    Crawford J
    J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
    [No Abstract]   [Full Text] [Related]  

  • 18. New pharmacoeconomic option in uremic anemia management.
    Savica V; Mantovani L; Santoro D; Ricciardi B; Bellinghieri G
    Clin Nephrol; 2007 Mar; 67(3):200. PubMed ID: 17390747
    [No Abstract]   [Full Text] [Related]  

  • 19. [Recent advances on the use of erythropoietin in oncology].
    Spaëth D
    Bull Cancer; 2006 May; 93(5):489-93. PubMed ID: 16777627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oversight put in place for physicians giving anemia drugs to patients with cancer.
    Mitka M
    JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.